Look for Drugs and Conditions

Representative Image

Bayer to present latest advanced oncology research findings at AACR 2023 annual meeting

German pharmaceutical and chemical major, Bayer announced that it will present the latest research across its oncology portfolio at the forthcoming American Association for Cancer Research (AACR) 2023 Annual Meeting.

According to a recent release, the company will share the outcomes of its cancer research in three areas during the convention, scheduled to be held from April 14 to 19 in Orlando, Florida.

Bayer informed that it is undertaking novel research around its prostate cancer drug, darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models.

The drug, developed collaboratively by Bayer and Orion Corporation, is an oral androgen receptor inhibitor indicated for the treatment of men with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease, as well as men with metastatic hormone-sensitive prostate cancer.

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology programme. The presentation will centre on the target engagement data and pharmacokinetics from its ongoing monotherapy dosage-escalation research to determine the best dose and timing for effectively inhibiting AhR. These findings, together with a mathematical model-informed approach, have backed up the current dose expansion for BAY 2416964.

In the New Drugs on the Horizon session at AACR, Bayer will present preclinical data on its novel selective diacylglycerol kinase (DGK) zeta inhibitor( BAY 2965501), which is under Phase 1 clinical evaluation. The enzyme DGKzeta is a lipid kinase that can down-modulate T-cell activation by catalyzing the conversion of diacylglycerol to phosphatidic acid, thus acting as a ligand-independent, intracellular immune checkpoint. An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumour antigens and has the potential to overcome multiple immune-suppressive mechanisms in the tumour microenvironment. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumours was initiated and is currently enrolling patients.

Both small molecule inhibitors in Immuno-Oncology are being jointly developed in a strategic research alliance with the German Cancer Research Center (DKFZ) in Heidelberg, Germany.

From its focus area Precision Molecular Oncology, Bayer will show new preclinical data on its mutEGFR/HER2 inhibitor, developed in collaboration with the Broad Institute of MIT and Harvard in Cambridge (MA), USA. BAY 2927088 is a reversible small molecule inhibitor, currently being evaluated in a first-in-human, Phase 1 clinical trial in non-small cell lung cancer (NSCLC) patients with mutations in epidermal growth factor receptors (EGFR & HER2), including exon20 insertions and point mutations. 

Bayer said that it will also report new data looking at larotrectinib, a highly selective and central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor, approved for the treatment of patients with TRK fusion solid tumours, exploring the concordance between tissue and circulating tumour DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions from samples in larotrectinib clinical trials.

Additionally, Bayer said that it will also be presenting its Targeted Alpha Therapy programme will be presented, assessing the antitumor activity and potential benefit of combining radium-223 with 177Lu-PSMA-617 in a preclinical model of bone metastatic prostate cancer. In a phase 1/2 experiment (AlphaBet, NCT05383079), the combination of radium-223 and 177Lu PSMA imaging and therapy (I&T) is being studied in patients with metastatic castration-resistant prostate cancer (mCRPC) during the conference.


0 Comments
Be first to post your comments

Post your comment

Related Articles

Ad 5